Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Guangdong Newopp Biopharmaceuticals Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. TOWNSLEY, SARA ELIZABETH is the busiest examiner, holding 1 pending action, which represents a portion of the company's current pending workload. For a practitioner, the ratio of pending actions to examiners suggests that each application is being reviewed by a different individual.
The involvement of 2 distinct art units may require tailoring technical arguments to the specific standards of each unit. With 2 pending office actions, the company maintains a small but diverse prosecution presence in the pharmaceutical sector. Practitioners should monitor the feedback from the 2 examiners to identify any common themes or divergent requirements. Because the workload is split between 2 distinct art units, the legal team must ensure that the technical disclosures are interpreted consistently. This profile represents a balanced approach to prosecution where no 1 examiner or art unit dominates the company's current pending interests in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18841312 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | TOWNSLEY, SARA ELIZABETH | — |
| 17556086 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18841312 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | TOWNSLEY, SARA ELIZABETH | — |
| 17556086 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18841312 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | TOWNSLEY, SARA ELIZABETH | 1629 | §102 | Non-Final OA | — | Pending | Aug 23, 2024 |
| 17556086 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | LADD, CAROLYN LOUISE | 1622 | §102§103 | Final Rejection | — | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangdong Newopp Biopharmaceuticals Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sara Elizabeth Townsley has the most, with 1 of Guangdong Newopp Biopharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
